EQ Equillium Inc

Price (delayed)

$1.67

Market cap

$58.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$36.48M

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing ...

Highlights

Equillium's debt has shrunk by 92% YoY and by 11% QoQ

The gross profit has soared by 129% YoY but it has contracted by 15% from the previous quarter

Equillium's revenue has soared by 129% YoY but it has decreased by 15% from the previous quarter

The quick ratio has contracted by 30% YoY and by 9% from the previous quarter

The equity has contracted by 29% YoY and by 6% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://equilliumbio.com

Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of EQ

Market

Shares outstanding

35.25M

Market cap

$58.88M

Enterprise value

$36.48M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.6

Price to sales (P/S)

1.61

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.01

Earnings

Revenue

$36.08M

EBIT

-$12.26M

EBITDA

-$12.14M

Free cash flow

-$21.83M

Per share

EPS

-$0.38

Free cash flow per share

-$0.63

Book value per share

$0.64

Revenue per share

$1.04

TBVPS

$1.46

Balance sheet

Total assets

$50.53M

Total liabilities

$27.96M

Debt

$824,000

Equity

$22.57M

Working capital

$21.78M

Liquidity

Debt to equity

0.04

Current ratio

1.79

Quick ratio

1.62

Net debt/EBITDA

1.84

Margins

EBITDA margin

-33.6%

Gross margin

100%

Net margin

-37%

Operating margin

-40.2%

Efficiency

Return on assets

-22.6%

Return on equity

-51.8%

Return on invested capital

-181.5%

Return on capital employed

-53.4%

Return on sales

-34%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EQ stock price

How has the Equillium stock price performed over time

Intraday

7.05%

1 week

-2.34%

1 month

-28.33%

1 year

199.02%

YTD

130.98%

QTD

-27.71%

Financial performance

How have Equillium's revenue and profit performed over time

Revenue

$36.08M

Gross profit

$36.08M

Operating income

-$14.52M

Net income

-$13.34M

Gross margin

100%

Net margin

-37%

The gross profit has soared by 129% YoY but it has contracted by 15% from the previous quarter

Equillium's revenue has soared by 129% YoY but it has decreased by 15% from the previous quarter

Equillium's net margin has shrunk by 92% QoQ but it has surged by 91% YoY

EQ's operating margin has soared by 90% YoY but it has plunged by 84% from the previous quarter

Growth

What is Equillium's growth rate over time

Valuation

What is Equillium stock price valuation

P/E

N/A

P/B

2.6

P/S

1.61

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.01

The EPS has surged by 79% year-on-year but it has dropped by 73% since the previous quarter

The price to book (P/B) is 160% higher than the last 4 quarters average of 1.0 and 63% higher than the 5-year quarterly average of 1.6

The equity has contracted by 29% YoY and by 6% from the previous quarter

Equillium's revenue has soared by 129% YoY but it has decreased by 15% from the previous quarter

The stock's P/S is 101% more than its last 4 quarters average of 0.8

Efficiency

How efficient is Equillium business performance

The return on sales has dropped by 110% since the previous quarter but it has surged by 91% year-on-year

The company's return on assets has shrunk by 82% QoQ but it has surged by 76% YoY

The ROE has plunged by 77% from the previous quarter but it has soared by 68% YoY

The ROIC has dropped by 57% since the previous quarter but it is up by 27% year-on-year

Dividends

What is EQ's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EQ.

Financial health

How did Equillium financials performed over time

The total assets is 81% greater than the total liabilities

EQ's total liabilities is down by 40% YoY and by 10% from the previous quarter

The total assets has declined by 36% year-on-year and by 9% since the previous quarter

Equillium's debt is 96% lower than its equity

Equillium's debt has shrunk by 92% YoY and by 11% QoQ

EQ's debt to equity has dropped by 88% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.